RemeGen’s $4.2 billion licensing deal falls flat with investors
The biopharma firm had fanned excitement over a rights deal for its autoimmune drug but the eventual terms, with just a small portion of upfront cash, left the market disappointed…
Dispute over Covid vaccines casts doubt on Clover Bio recovery
The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
BeiGene heads for profit milestone after hemorrhaging cash
With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…
Recent Articles
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK
688331.SHG
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK
ONC.US
688235.SHG
RELATED ARTICLES
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG -
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
